Effects of the proteasome inhibitor ps-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts

Molecular Cancer Therapeutics

Volumn 1, Issue 14, 2002, Pages 1243-1253

  Nawrocki, Steffan T ^a   Bruns, Christiane J ^a   Harbison, Matthew T ^a   Bold, Richard J ^a   Gotsch, Bridget Sweeney ^a   Abbruzzese, James L ^a   Elliott, Peter ^b   Adams, Julian ^b   McConkey, David J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYSTEINE PROTEINASE; DNA FRAGMENT; ENDOTHELIAL CELL GROWTH FACTOR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOKINE; MULTIENZYME COMPLEX; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; PROTEASOME; PROTEINASE INHIBITOR; SIGNAL PEPTIDE; VASCULOTROPIN; VASCULOTROPIN A;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL DIVISION; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IC 50; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PANCREAS TUMOR; PATHOLOGY; TIME; VASCULARIZATION;

ANIMALS; APOPTOSIS; CASPASES; CELL DIVISION; CELL SURVIVAL; CYSTEINE ENDOPEPTIDASES; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; I-KAPPA B PROTEINS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MALE; MICE; MICE, INBRED BALB C; MULTIENZYME COMPLEXES; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PANCREATIC NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0012433771     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Wingo, P. A., Tong, T., and Bolden, S. Cancer statistics, 1995. CA - Cancer J. Clin., 45: 8-30, 1995.
2. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1999 [see comments]. CA - Cancer J. Clin., 49: 8-31, 1999. (Pubitemid 29094959)
3. Evans, D. B., Lee, J. E., Pisters, P. W., Charnsangavej, C., Ellis, L. M., Chiao, P. J., Lenzi, R., and Abbruzzese, J. L. Advances in the diagnosis and treatment of adenocarcinoma of the pancreas. Cancer Treat. Res., 90: 109-125, 1997.
4. Hilgers, W., and Kern, S. E. Molecular genetic basis of pancreatic adenocarcinoma. Genes Chromosomes Cancer, 26: 1-12, 1999. (Pubitemid 29374856)
5. Brentnall, T. A., Chen, R., Lee, J. G., Kimmey, M. B., Bronner, M. P., Haggitt, R. C., Kowdley, K. V., Hecker, L. M., and Byrd, D. R. Microsatellite instability and K-ras mutations associated with pancreatic adenocarcinoma and pancreatitis. Cancer Res., 55: 4264-4267, 1995.
6. Banerjee, S. K., Makdisi, W. F., Weston, A. P., and Campbell, D. R. A two-step enriched-nested PCR technique enhances sensitivity for detection of codon 12 K-ras mutations in pancreatic adenocarcinoma. Pancreas, 15: 16-24, 1997. (Pubitemid 27527355)
7. Mayo, M. W., Wang, C. Y., Cogswell, P. C., Rogers-Graham, K. S., Lowe, S. W., Der, C. J., and Baldwin, A. S., Jr. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science (Wash. DC), 278: 1812-1815, 1997. (Pubitemid 27527651)
8. Fenwick, C., Na, S. Y., Voll, R. E., Zhong, H., Im, S. Y., Lee, J. W., and Ghosh, S. A subclass of Ras proteins that regulate the degradation of IκB. Science (Wash. DC), 287: 869-873, 2000. (Pubitemid 30084332)
9. Wang, W., Abbruzzese, J. L., Evans, D. B., Larry, L., Cleary, K. R., and Chiao, P. J. The nuclear factor κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res., 59: 119-127, 1999. (Pubitemid 29045184)
10. Wang, C. Y., Mayo, M. W., and Baldwin, A. S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NFkB. Nature (Lond.), 274: 784-787, 1996. (Pubitemid 26398259)
11. Wang, C., Mayo, M., Korneluk, R., Goeddel, D., and Baldwin, A. NFkB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science (Wash. DC), 281: 1680-1683, 1998.
12. Wang, C. Y., Cusack, J. C., Liu, R., and Baldwin, A. S. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NFkB. Nat. Med., 5: 412-417, 1999. (Pubitemid 29180579)
13. Goldberg, A. L., Stein, R., and Adams, J. New insights into proteasome function: from archaebacteria to drug development. Chem. Biol., 2: 503-508, 1995.
14. Chambers, A. F., MacDonald, I. C., Schmidt, E. E., Koop, S., Morris, V. L., Khokha, R., and Groom, A. C. Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev., 14: 279-301, 1995. (Pubitemid 26027931)
15. Palombella, V. J., Rando, O. J., Goldberg, A. L., and Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-kB1 precursor protein and the activation of NF-kB. Cell, 78: 773-785, 1994. (Pubitemid 24294453)
16. Traenckner, E. B. M., Wilk, S., and Baeuerle, P. A. A proteasome inhibitor prevents activation of NF-kB and stabilizes a newly phosphorylated form of IkB-a that is still bound to NF-kB. EMBO J., 13: 5433-5441, 1994. (Pubitemid 24351822)
17. Baeuerle, P. A., and Baltimore, D. NFkB: ten years after. Cell, 87: 13-20, 1996.
18. Henkel, T., Machleidt, T., Alkalay, I., Kronke, M., Ben-Neriah, Y., and Baeuerle, P. A. Rapid proteolysis of IkBa is necessary for activation of the transcription factor NFkB. Nature (Lond.), 365: 182-185, 1993. (Pubitemid 23282067)
19. Beg, A. A., Finco, T. S., Nantermet, P. V., and Baldwin, A. S., Jr. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IκBα: a mechanism for NF-κB activation. Mol. Cell. Biol., 13: 3301-3310, 1993. (Pubitemid 23157268)
20. Drexler, H. C. A. Activation of the cell death program by inhibition of proteasome function. Proc. Natl. Acad. Sci. USA, 94: 855-860, 1997. (Pubitemid 27074411)
21. Chandra, J., Niemer, I., Gilbreath, J., Kliche, K. O., Andreeff, M., Freireich, E. J., Keating, M., and McConkey, D. J. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood, 92: 4220-4229, 1998. (Pubitemid 28544338)
22. Drexler, H. C. A. Programmed cell death and the proteasome. Apoptosis, 3: 1-7, 1998. (Pubitemid 128511999)
23. Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J., Destree, A., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., and Elliott, P. J. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res., 59: 2615-2622, 1999. (Pubitemid 29269108)
24. Bruns, C. J., Harbison, M. T., Kuniyasu, H., Eue, I., and Fidler, I. J. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia, 1: 50-62, 1999.
25. Bold, R. J., Chandra, J., and McConkey, D. J. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by BCL-2 content. Ann. Surg. Oncol., 6: 279-285, 1999. (Pubitemid 29221014)
26. McConkey, D. J., Greene, G., and Pettaway, C. A. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res. 56: 5594-5599, 1996. (Pubitemid 26422158)
27. Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., and Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods, 139: 271-279, 1991.
28. Lightcap, E. S., McCormack, T. A., Pien, C. S., Chau, V., Adams, J., and Elliott, P. J. Proteasome inhibition measurements: clinical application. Clin. Chem., 46: 673-683, 2000. (Pubitemid 30318423)
29. Fernandez, A., Fosdick, L. J., Marin, M. C., Diaz, C., McDonnell, T. J., Ananthaswamy, H. N., and McConkey, D. J. Differential regulation of endogenous endonuclease activation in isolated murine fibroblast nuclei by ras and bcl-2. Oncogene, 10: 769-774, 1995.
30. Davis, D. W., Weidner, D. A., Holian, A., and McConkey, D. J. Nitric oxide-dependent activation of p53 suppresses bleomycin-induced apoptosis in the lung. J. Exp. Med., 192: 857-869, 2000.
31. Bruns, C. J., Solorzano, C. C., Harbison, M. T., Ozawa, S., Tsan, R., Fan, D., Abbruzzese, J., Traxler, P., Buchdunger, E., Radinsky, R., and Fidler, I. J. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res., 60: 2926-2935, 2000. (Pubitemid 30395817)
32. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fournace, A. J., and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute's anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997. (Pubitemid 27413438)
33. Herrmann, J. L., Briones, F., Jr., Brisbay, S., Logothetis, C. J., and McDonnell, T. J. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene, 17: 2889-2899, 1998. (Pubitemid 29010059)
34. Cusack, J. C., Jr., Liu, R., Houston, M., Abendroth, K., Elliott, P. J., Adams, J., and Baldwin, A. S., Jr. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor κB inhibition. Cancer Res., 61: 3535-3540, 2001. (Pubitemid 32694955)
35. Hruban, R. H., Goggins, M., Parsons, J., and Kern, S. E. Progression model for pancreatic cancer. Clin. Cancer Res., 6: 2969-2972, 2000. (Pubitemid 30637716)
36. Chen, F., Castranova, V., and Shi, X. New insights into the role of nuclear factor κB in cell growth regulation. Am. J. Pathol., 159: 387-397, 2001. (Pubitemid 32751067)
37. Bours, V., Bentires-Alj, M., Hellin, A. C., Viatour, P., Robe, P., Delhalle, S., Benoit, V., and Merville, M. P. Nuclear factor-κ B, cancer, and apoptosis. Biochem. Pharmacol., 60: 1085-1089, 2000.
38. Frankel, A., Man, S., Elliott, P., Adams, J., and Kerbel, R. S. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin. Cancer Res., 6: 3719-3728, 2000.
39. Sunwoo, J. B., Chen, Z., Dong, G., Yeh, N., Crowl Bancroft, C., Sausville, E., Adams, J., Elliott, P., and Van Waes, C. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res., 7: 1419-1428, 2001. (Pubitemid 32708698)
40. Bruns, C. J., Harbison, M. T., Davis, D. W., Portera, C. A., Tsan, R., McConkey, D. J., Evans, D. B., Abbruzzese, J. L., Hicklin, D. J., and Radinsky, R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res., 6: 1936-1948, 2000. (Pubitemid 30305093)